MannKind Corporation (MNKD)

Oncology Corporate Profile

Stock Performance


HQ Location

28903 North Avenue Paine
Valencia, CA 91355

Company Description

MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MKC1106immunotherapy1st line metastatic MelanomaII
MKC204IRE-1? InhibitorMultiple MyelomaPreclinical


Recent News Headlines

MannKind posts 4Q profit

3/16/2017 08:03 pm

MannKind posts 4Q profit

3/16/2017 08:03 pm

MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results

3/16/2017 08:00 pm

[GlobeNewswire] - Conference Call to Begin Today at 5:00 PM ET. VALENCIA, Calif., March 16, 2017-- MannKind Corporation today reported financial results for the fourth quarter and full year ended December 31, 2016. Total ...

When Profit Makers Can Be Active Profit Takers

3/16/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 16, 2017 / The inside investors of Exelixis and MannKind corporations have sold some of their company stock today. One Director cashed in on a $20 a share price increase, ...

MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes

3/8/2017 02:00 pm

[GlobeNewswire] - VALENCIA, Calif. and TAMPA, Fla., March 08, 2017-- MannKind Corporation and Bella & Elle Media LLC announce MannKind’ s sponsorship of“ Reversed,” a production series aimed at educating the show’ s participants ...

MannKind Corporation Announces Upcoming Events

3/7/2017 02:00 pm

[GlobeNewswire] - -29th Annual ROTH Conference on March 13, 2017-- 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 16, 2017-. VALENCIA, Calif., March 07, 2017-- MannKind Corporation announced ...

3 Stocks to Avoid in Biotech

2/28/2017 04:00 pm